Biocause Pharma(SZ:000627) Zheng Quan Zhi Xing·2025-08-08 15:17Group 1 - The company held its fourth meeting of the tenth board on August 8, 2025, to review and approve amendments to the Articles of Association and related rules [1] - The company approved a share buyback plan on July 1, 2024, with a total fund of no less than RMB 50 million and no more than RMB 100 million, at a maximum price of RMB 3.34 per share [1][2] - The company completed the buyback of 36,490,000 shares, accounting for 0.7386% of the total share capital, with a total transaction amount of RMB 99,982,600 [2] Group 2 - The company plans to adjust its internal supervisory structure by abolishing the supervisory board and supervisors, transferring the supervisory powers to the audit committee of the board [2] - The supervisory board and supervisors will continue to perform their duties until the shareholders' meeting approves the proposal [2] - The amendments to the Articles of Association are in accordance with the new Company Law and other relevant regulations [3] Group 3 - The amendments to the Articles of Association include provisions for the appointment of a new legal representative within 30 days of the resignation of the current one [3][4] - The company will ensure that all shareholders have equal rights and obligations regarding their shares [4][5] - The company will not provide financial assistance to any person for acquiring its shares, except for employee stock ownership plans [5][6]